1 PRODUCT NAME
VOLTAREN® 75 mg/3 mL Solution for injection

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ampoule of 3 mL contains 75 mg of diclofenac sodium.
For the full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM
Solution for injection.

4 CLINICAL PARTICULARS
4.1 Therapeutic indications

Intramuscular injection
Treatment of:
- Renal colic and biliary colic.
- Severe migraine attacks when other forms of Voltaren are considered unsuitable.

Intramuscular injection
Treatment or prevention of post-operative pain in a hospital setting.

4.2 Dose and method of administration
Voltairen should only be prescribed when the benefits are considered to outweigh the potential risks.
After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used. Adverse effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4).

Dosage

General population
Voltairen solution for injection should not be given for more than 2 days; if necessary, treatment can be continued with Voltairen tablets or suppositories.

Special populations

Paediatric population
Because of their dosage strength, the ampoules of Voltairen solution for injection are not suitable for children and adolescents.

Geriatric population (Patients aged 65 or above)
No adjustment of the starting dose is generally required for elderly patients However, caution is indicated on basic medical grounds, especially for frail elderly patients or those with a low body weight (see section 4.4).

Patients with established cardiovascular disease or significant cardiovascular risk factors
Treatment with Voltairen solution for injection is generally not recommended in patients with established cardiovascular disease or uncontrolled hypertension. If needed, patients with established cardiovascular disease, uncontrolled hypertension or significant risk factors for cardiovascular disease
should be treated with Voltaren solution for injection only after careful consideration and only at doses ≤100 mg daily. Initial treatment with Voltaren solution for injection continues e.g. with Voltaren tablets or suppositories for more than 4 weeks (see section 4.4).

**Patients with renal impairment**
Voltaren is contraindicated in patients with renal failure (see section 4.3).

No specific studies have been carried out in patients with renal impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Voltaren to patients with renal impairment (see section 4.4).

**Patients with hepatic impairment**
Voltaren is contraindicated in patients with hepatic failure (see section 4.3).

No specific studies have been carried out in patients with hepatic impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Voltaren to patients with mild to moderate hepatic impairment (see section 4.4).

**Method of Administration**

**Intramuscular injection**

The following directions for intramuscular injection must be followed in order to avoid damage to a nerve or other tissue at the injection site (which may result in muscle weakness, muscle paralysis and hypoaesthesia).

The dose is generally one 75 mg ampoule daily, given by deep intragluteal injection into the upper outer quadrant using aseptic technique. In severe cases (e.g. colic), the daily dose can exceptionally be increased to two injections of 75 mg, separated by an interval of a few hours (one into each buttock). Alternatively, one ampoule of 75 mg can be combined with other pharmaceutical forms of Voltaren (e.g. tablets, suppositories) up to a total maximum daily dose of 150 mg.

In migraine attacks, clinical experience is limited to initial use of one ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dose should not exceed 175 mg on the first day.
Intravenous infusion
Voltaren solution for injection must not be given as an intravenous bolus injection. Immediately before starting an intravenous infusion, Voltaren solution for injection must be diluted with saline 0.9% or glucose 5% infusion solution buffered with sodium bicarbonate according to the instructions given in section 6.6.

Two alternative dosage regimens of Voltaren solution for injection are recommended.

For the treatment of moderate to severe post-operative pain, 75 mg should be infused continuously over a period of 30 minutes to 2 hours. If necessary, treatment may be repeated after a few hours, but the dose should not exceed 150 mg within any period of 24 hours.

For the prevention of post-operative pain, a loading dose of 25 mg to 50 mg should be infused after surgery over 15 minutes to 1 hour, followed by a continuous infusion of about 5 mg per hour up to a maximum daily dose of 150 mg.

4.3 Contraindications
- Known hypersensitivity to the active substance, sodium metabisulphite or to any of the excipients (see section 6.1).
- Active gastric or intestinal ulcer, bleeding or perforation.
- Last trimester of pregnancy (see section 4.6).
- Hepatic failure.
- Renal failure (GFR <15 mL/min/1.73m²).
- Severe cardiac failure (see section 4.4).
- Like other non-steroidal anti-inflammatory drugs (NSAIDs), Voltaren is also contraindicated in patients in whom attacks of asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs.

4.4 Special warnings and precautions for use

General
Patients on long-term treatment should be reviewed regularly with regards to efficacy, adverse effects, the development of risk factors and the on-going need for therapy. Consideration should be given to monitoring blood pressure, haemoglobin levels and renal function.

Cardiovascular thrombotic events
Observational studies have indicated that non-selective NSAIDs may be associated with an increased risk of serious cardiovascular events including myocardial infarction and stroke, which may increase with dose or duration of use. Patients with cardiovascular disease or cardiovascular risk factors may also be at greater risk.

Patients with previous myocardial infarction (within the last 6 to 12 months) should not use diclofenac. Treatment with Voltaren is generally not recommended in patients with established cardiovascular disease (e.g. congestive heart failure, established ischaemic heart disease, peripheral arterial disease) or uncontrolled hypertension. If needed, patients with established cardiovascular disease, uncontrolled hypertension or significant risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus and smoking) should be treated with Voltaren only after careful consideration and only at doses ≤100 mg daily when treatment continues for more than 4 weeks.
As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the lowest effective daily dose should be used for the shortest duration possible (see section 4.2). The patient’s need for symptomatic relief and response to therapy should be reevaluated periodically, especially when treatment continues for more than 4 weeks.

Prescribers should inform the individual patient of the possible increased risk when prescribing diclofenac for patients at high risk of cardiovascular events.

Physicians and patients should remain alert for such events, even in the absence of previous cardiovascular symptoms. Patients should be informed about the signs and/or symptoms of cardiovascular toxicity and the steps to take should they occur. Patients should remain alert for the signs and symptoms of serious arteriothrombotic events (e.g. chest pain, shortness of breath, weakness, slurring of speech), which can occur without warning. Patients should be instructed to see a physician immediately in case of such an event.

There is no consistent evidence that the concurrent use of aspirin mitigates the possible increased risk of serious cardiovascular thrombotic events associated with NSAID use.

**Hypertension**

NSAIDs may lead to the onset of new hypertension or worsening of pre-existing hypertension and patients taking anti-hypertensives with NSAIDs may have an impaired anti-hypertensive response. Caution is advised when prescribing NSAIDs to patients with hypertension. Blood pressure should be monitored closely during initiation of NSAID treatment and at regular intervals thereafter.

**Heart failure**

Fluid retention and oedema have been observed in some patients taking NSAIDs, therefore caution is advised in patients with fluid retention or heart failure.

**Gastrointestinal effects**

Gastrointestinal bleeding, ulceration or perforation, which may increase with dose or duration of use and which can be fatal, have been reported with all NSAIDs, including diclofenac, and may occur at any time during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. They generally have more serious consequences in the elderly. If gastrointestinal bleeding or ulceration occur in patients receiving Voltaren, the treatment should be discontinued.

Upper GI ulcers, gross bleeding or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months and in about 2-4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.

Caution is advised in patients with risk factors for gastrointestinal events who may be at greater risk of developing serious gastrointestinal events, e.g. the elderly, those with a history of serious gastrointestinal events, smoking and alcoholism.

As with all NSAIDs, including diclofenac, close medical surveillance is imperative and particular caution should be exercised when prescribing Voltaren in patients with symptoms indicative of gastrointestinal (GI) disorders or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation (see section 4.8). The risk of GI bleeding is higher with increasing NSAID doses and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation and in the elderly.

To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation, and in the elderly, the treatment should be initiated and maintained at the lowest effective dose.
Combination therapy with protective agents (e.g. proton pump inhibitors or misoprostol) should be considered for these patients, and also for patients requiring concomitant use of medicinal products containing low-dose acetylsalicylic acid (ASA)/aspirin or other medicinal products likely to increase gastrointestinal risk.

Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially GI bleeding). Caution is recommended in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants, anti-platelet agents or selective serotonin-reuptake inhibitors (see section 4.5).

Close medical surveillance and caution should also be exercised in patients with ulcerative colitis or Crohn’s disease, as their condition may be exacerbated (see section 4.8).

The concurrent use of aspirin and NSAIDs also increases the risk of serious gastrointestinal adverse events.

Doctors should warn patients about the signs and symptoms of serious gastrointestinal toxicity.

**Severe skin reactions**

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported very rarely in association with the use of NSAIDs, including Voltaren (see section 4.8). These serious adverse events are idiosyncratic and are independent of dose or duration of use. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Patients should be advised of the signs and symptoms of serious skin reactions and to consult their doctor at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, and Voltaren should be discontinued.

As with other NSAIDs, allergic reactions, including anaphylactic/anaphylactoid reactions, can also occur in rare cases with diclofenac, without earlier exposure to the drug.

The sodium metabisulphite in the solution for injection can also lead to isolated severe hypersensitivity reactions and bronchospasm.

**Masking signs of infections**

Like other NSAIDs, Voltaren may mask the signs and symptoms of infection due to its pharmacodynamic properties.

**Pre-existing asthma**

In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e. nasal polyps), chronic obstructive pulmonary diseases or chronic infections of the respiratory tract (especially if linked to allergic rhinitis-like symptoms), reactions on NSAIDs like asthma exacerbations (so-called intolerance to analgesics/analgesics-asthma), Quincke’s oedema or urticaria are more frequent than in other patients. Therefore, special precaution is recommended in such patients (readiness for emergency). This is applicable as well for patients who are allergic to other substances, e.g. with skin reactions, pruritus or urticaria.

Special caution is recommended when Voltaren is used parenterally in patients with bronchial asthma because symptoms may be exacerbated.

**Hepatic effects**

Close medical surveillance is required when prescribing Voltaren to patients with impaired hepatic function, as their condition may be exacerbated.

As with other NSAIDs, including diclofenac, values of one or more liver enzymes may increase. During prolonged treatment with Voltaren, regular monitoring of hepatic function is indicated as a
precautionary measure. If abnormal liver function tests persist or worsen, if clinical signs or symptoms consistent with liver disease develop, or if other manifestations occur (e.g. eosinophilia, rash), Voltaren should be discontinued. Hepatitis may occur with use of diclofenac without prodromal symptoms.

Caution is called for when using Voltaren in patients with hepatic porphyria, since it may trigger an attack.

**Renal effects**

As fluid retention and oedema have been reported in association with NSAID therapy, including diclofenac, particular caution is called for in patients with impaired cardiac or renal function, history of hypertension, the elderly, patients receiving concomitant treatment with diuretics or medicinal products that can significantly impact renal function, and in those patients with substantial extracellular volume depletion from any cause, e.g. before or after major surgery (see section 4.3). Monitoring of renal function is recommended as a precautionary measure when using Voltaren in such cases. Discontinuation of therapy is usually followed by recovery to the pre-treatment state.

**Haematological effects**

During prolonged treatment with Voltaren, as with other NSAIDs, monitoring of the blood count is recommended.

Like other NSAIDs, Voltaren may temporarily inhibit platelet aggregation. Patients with defects of haemostasis should be carefully monitored.

**Geriatric patients**

Caution is indicated in the elderly on basic medical grounds. In particular, it is recommended that the lowest effective dose be used in frail elderly patients or those with a low body weight (see section 4.2).

**Interactions with other NSAIDs**

The concomitant use of Voltaren with systemic NSAIDs including cyclooxygenase-2 selective inhibitors, should be avoided due to the absence of any evidence demonstrating synergistic benefits and the potential for additive undesirable effects (see section 4.5).

4.5 Interaction with other medicines and other forms of interaction

The following interactions include those observed with Voltaren solution for injection and/or other pharmaceutical forms of diclofenac.

**Observed interactions to be considered**

**CYP2C9 inhibitors:** Caution is recommended when co-prescribing diclofenac with potent CYP2C9 inhibitors (such as sulfinpyrazone and voriconazole), which could result in a significant increase in peak plasma concentrations and exposure to diclofenac due to inhibition of diclofenac metabolism.

**Lithium:** If used concomitantly, diclofenac may raise plasma concentrations of lithium. Monitoring of the serum lithium level is recommended.

**Digoxin:** If used concomitantly, diclofenac may raise plasma concentrations of digoxin. Monitoring of the serum digoxin level is recommended.

**Diuretics and antihypertensive agents:** Like other NSAIDs, concomitant use of diclofenac with diuretics or antihypertensive agents (e.g. beta-blockers, angiotensin converting enzyme (ACE) inhibitors) may cause a decrease in their antihypertensive effect. Therefore, the combination should be administered with caution and patients, especially the elderly should have their blood pressure
periodically monitored. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter, particularly for diuretics and ACE inhibitors due to the increased risk of nephrotoxicity. (see section 4.4).

**Other NSAIDs and corticosteroids:** Concomitant administration of diclofenac and other systemic NSAIDs or corticosteroids may increase the frequency of gastrointestinal undesirable effects (see section 4.4).

**Anticoagulants and anti-platelet agents:** Caution is recommended since concomitant administration could increase the risk of bleeding (see section 4.4). Although clinical investigations do not appear to indicate that diclofenac affects the action of anticoagulants, there are reports of an increased risk of haemorrhage in patients receiving diclofenac and anticoagulants concomitantly. Close monitoring of such patients is therefore recommended.

**Selective serotonin reuptake inhibitors (SSRIs):** Concomitant administration of systemic NSAIDs, including diclofenac, and SSRIs may increase the risk of gastrointestinal undesirable effects (see section 4.4).

**Antidiabetics:** Clinical studies have shown that diclofenac can be given together with oral antidiabetic agents without influencing their clinical effect. However, there have been isolated reports of both hypoglycaemic and hyperglycaemic effects necessitating changes in the dosage of the antidiabetic agents during treatment with diclofenac. For this reason, monitoring of the blood glucose level is recommended as a precautionary measure during concomitant therapy.

There have also been isolated reports of metabolic acidosis when diclofenac was co-administered with metformin, especially in patients with pre-existing renal impairment.

**Methotrexate:** Caution is recommended when NSAIDs, including diclofenac, are administered less than 24 hours before or after treatment with methotrexate, since blood concentrations of methotrexate may rise and the toxicity of this substance be increased.

**Cyclosporin and Tacrolimus:** Diclofenac, like other NSAIDs, may increase the nephrotoxicity of cyclosporin and tacrolimus due to the effect on renal prostaglandins. Therefore, it should be given at doses lower than those that would be used in patients not receiving cyclosporin and tacrolimus.

**Drugs known to cause hyperkalemia:** Concomitant treatment with potassium-sparing diuretics, ciclosporin, tacrolimus or trimethoprim may be associated with increased serum potassium levels, which should therefore be monitored frequently (see section 4.4)

**Quinolone antibacterials:** There have been isolated reports of convulsions which may have been due to concomitant use of quinolones and NSAIDs.

**Phenytoin:** When using phenytoin concomitantly with diclofenac, monitoring of phenytoin plasma concentrations is recommended due to an expected increase in exposure to phenytoin.

**CYP2C9 inducers:** Caution is recommended when co-prescribing diclofenac with CYP2C9 inducers (such as rifampicin), which could result in a significant decrease in plasma concentration and exposure to diclofenac.

### 4.6 Fertility, pregnancy and lactation

**Use in Pregnancy**

There are insufficient data on the use of diclofenac in pregnant women. Therefore, Voltaren should not be used during the first two trimesters of pregnancy unless the expected benefits to the mother outweigh the risks to the foetus. As with other NSAIDs, use of diclofenac during the third trimester of pregnancy is contraindicated owing to the possibility of uterine inertia, fetal renal impairment with subsequent oligohydramnios and/or premature closure of the ductus arteriosus (see section 4.3 and 5.3).
Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo/fetal development. Data from some epidemiological studies suggest an increased risk of miscarriage after use of a prostaglandin synthesis inhibitor (such as NSAIDs) in early pregnancy, however the overall data from the available studies is inconclusive. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss. During the first and second trimester of pregnancy, Voltaren should not be given unless clearly necessary. If Voltaren is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible.

**Breastfeeding**

Like other NSAIDs, diclofenac passes into the breast milk in small amounts. Therefore, Voltaren should not be administered during breast feeding in order to avoid undesirable effects in the infant.

**Fertility**

As with other NSAIDs, the use of Voltaren may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of Voltaren should be considered.

**4.7 Effects on ability to drive and use machines**

Patients who experience visual disturbances, dizziness, vertigo, somnolence, central nervous system disturbances, drowsiness, or fatigue while taking NSAIDs should refrain from driving or operating machinery.

**4.8 Undesirable effects**

Adverse drug reactions from clinical trials and/or spontaneous or literature reports (Table 1) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (>1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000).

The following undesirable effects include those reported with Voltaren solution for injection and/or other pharmaceutical forms of diclofenac, with either short-term or long-term use.

**Table 1 Adverse drug reactions**

<table>
<thead>
<tr>
<th>Infections and infestations</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Very rare:</td>
<td>Injection site abscess</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blood and lymphatic system disorders</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Very rare:</td>
<td>Thrombocytopenia, leukopenia, anaemia (including haemolytic and aplastic anaemia), agranulocytosis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Immune system disorders</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare:</td>
<td>Hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock).</td>
</tr>
<tr>
<td>Very rare:</td>
<td>Angioedema (including face oedema).</td>
</tr>
</tbody>
</table>

**Psychiatric disorders**


<table>
<thead>
<tr>
<th><strong>Nervous system disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Very rare:</strong></td>
<td>Disorientation, depression, insomnia, nightmare, irritability, psychotic disorder.</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Headache, dizziness.</td>
</tr>
<tr>
<td><strong>Rare:</strong></td>
<td>Somnolence.</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>Paraesthesia, memory impairment, convulsion, anxiety, tremor, meningitis aseptic, dysgeusia, cerebrovascular accident.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Eye disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Very rare:</strong></td>
<td>Visual impairment, blurred vision, diplopia.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ear and labyrinth disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common:</strong></td>
<td>Vertigo.</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>Tinnitus, impaired hearing</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Cardiac disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em><em>Uncommon</em>:</em>*</td>
<td>Myocardial infarction, cardiac failure, palpitations, chest pain.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Vascular disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Very rare:</strong></td>
<td>Hypertension, vasculitis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Respiratory, thoracic and mediastinal disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rare:</strong></td>
<td>Asthma (including dyspnoea).</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>Pneumonitis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Gastrointestinal disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common</strong></td>
<td>Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, anorexia.</td>
</tr>
<tr>
<td><strong>Rare:</strong></td>
<td>Gastritis, gastrointestinal haemorrhage, haematemesis, melaena, haemorrhagic diarrhoea, gastrointestinal ulcer (with or without bleeding gastrointestinal stenosis or perforation which may lead to peritonitis).</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>Colitis (including haemorrhagic colitis, ischemic colitis and exacerbation of ulcerative colitis or Crohn’s disease), constipation, stomatitis, glossitis, oesophageal disorder, intestinal diaphragm disease, pancreatitis, haemorrhoids aggravated.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Hepatobiliary disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common:</strong></td>
<td>Transaminases increased.</td>
</tr>
<tr>
<td><strong>Rare:</strong></td>
<td>Hepatitis, jaundice, liver disorder.</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>Fulminant hepatitis, hepatic necrosis, hepatic failure.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Skin and subcutaneous tissue disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common:</strong></td>
<td>Rash.</td>
</tr>
<tr>
<td><strong>Rare:</strong></td>
<td>Urticaria.</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>Bullous dermatitis, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome), exfoliative dermatitis, alopecia, photosensitivity reaction, allergic purpura, Henoch-Schonlein purpura, pruritus.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Renal and urinary disorders</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Very rare:</strong></td>
<td>Acute kidney injury (acute renal failure), haematuria, proteinuria, nephrotic syndrome, tubulointerstitial nephritis, renal papillary necrosis.</td>
</tr>
</tbody>
</table>
General disorders and administration site conditions

<table>
<thead>
<tr>
<th>Common</th>
<th>Rare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection site reaction, injection site pain,</td>
<td>Oedema, injection site necrosis</td>
</tr>
<tr>
<td>injection site induration</td>
<td></td>
</tr>
</tbody>
</table>

* The frequency reflects data from long-term treatment with a high dose (150 mg/day)

Description of selected adverse reactions

Arteriothrombotic events

Meta-analysis and pharmacoepidemiological data point towards a small increased risk of arteriothrombotic events (for example myocardial infarction) associated with the use of diclofenac, particularly at a high dose (150 mg daily) and during long-term treatment (see section 4.4).

Visual effects

Visual disturbances such as visual impairment, blurred vision or diplopia appear to be NSAID class effects and are usually reversible on discontinuation. A likely mechanism for the visual disturbances is the inhibition of prostaglandin synthesis and other related compounds that alter the regulation of retinal blood flow resulting in potential changes in vision. If such symptoms occur during diclofenac treatment, an ophthalmological examination may be considered to exclude other causes.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/).

4.9 Overdose

Symptoms

There is no typical clinical picture resulting from diclofenac overdosage. Overdosage can cause symptoms such as vomiting, gastrointestinal haemorrhage, diarrhoea, dizziness, tinnitus or convulsions. In the event of significant poisoning, acute renal failure and liver damage are possible.

Therapeutic measures

Management of acute poisoning with NSAIDs, including diclofenac, essentially consists of supportive measures and symptomatic treatment. Supportive measures and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastrointestinal disorder, and respiratory depression.

Special measures such as forced diuresis, dialysis or haemoperfusion are probably of no help in eliminating NSAIDs, including diclofenac, due to the high protein binding and extensive metabolism.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: anti-inflammatory and antirheumatic products, non-steroids, acetic acid derivatives and related substances (ATC code: M01A B05).

Mechanism of action
Voltaren contains diclofenac sodium, a non-steroidal compound with pronounced antirheumatic, anti-inflammatory, analgesic, and antipyretic properties. Inhibition of prostaglandin biosynthesis, which has been demonstrated in experiments, is considered fundamental to its mechanism of action. Prostaglandins play a major role in causing inflammation, pain, and fever.

Diclofenac sodium in vitro does not suppress proteoglycan biosynthesis in cartilage at concentrations equivalent to those reached in humans.

**Pharmacodynamic effects**

In rheumatic diseases, the anti-inflammatory and analgesic properties of Voltaren elicit a clinical response characterised by marked relief from signs and symptoms such as pain at rest, pain on movement, morning stiffness, and swelling of the joints, as well as by an improvement in function.

Voltaren has also been found to exert a pronounced analgesic effect in moderate and severe pain of non-rheumatic origin, an effect which sets in within 15 to 30 minutes.

Voltaren has also been shown to have a beneficial effect in migraine attacks.

In post-traumatic and post-operative inflammatory conditions, Voltaren rapidly relieves both spontaneous pain and pain on movement and reduces inflammatory swelling and wound oedema.

When used concomitantly with opioids for the management of post-operative pain, Voltaren significantly reduces the need for opioids.

Voltaren ampoules are particularly suitable for initial treatment of inflammatory and degenerative rheumatic diseases, and of painful conditions due to inflammation of non-rheumatic origin.

**5.2 Pharmacokinetic properties**

**Absorption**

After administration of 75 mg diclofenac by intramuscular injection, absorption sets in immediately, and mean peak plasma concentrations of about 2.5 micrograms/mL (8 micromol/L) are reached after about 20 minutes. When 75 mg diclofenac is administered as an intravenous infusion over 2 hours, mean peak plasma concentrations are about 1.9 micrograms/mL (5.9 micromol/L). Shorter infusions result in higher peak plasma concentrations, while longer infusions give plateau concentrations proportional to the infusion rate after 3 to 4 hours. In contrast, plasma concentrations decline rapidly once peak levels have been reached following intramuscular injection or administration of gastro-resistant tablets or suppositories.

The area under the concentration curve (AUC) after intramuscular or intravenous administration is about twice as large as it is following oral or rectal administration, because about half the active substance is metabolised during its first passage through the liver ("first pass" effect) when administered via the oral or rectal routes.

Pharmacokinetic behaviour does not change after repeated administration. No accumulation occurs provided the recommended dosage intervals are observed.

**Distribution**

99.7% of diclofenac is bound to serum proteins, mainly to albumin 99.4%). The apparent volume of distribution calculated is 0.12 to 0.17 L/kg.

Diclofenac enters the synovial fluid, where maximum concentrations are measured 2 to 4 hours after peak plasma values have been attained. The apparent half-life for elimination from the synovial fluid is 3 to 6 hours. Two hours after reaching peak plasma values, concentrations of the active substance are already higher in the synovial fluid than in the plasma, and they remain higher for up to 12 hours.
Diclofenac was detected in a low concentration (100 ng/mL) in breast milk in one nursing mother. The estimated amount ingested by an infant consuming breast milk is equivalent to a 0.03 mg/kg/day dose.

**Metabolism**

Biotransformation of diclofenac takes place partly by glucuronidation of the intact molecule, but mainly by single and multiple hydroxylation and methoxylation, resulting in several phenolic metabolites (3'-hydroxy-, 4'-hydroxy-, 5-hydroxy-, 4',5'-dihydroxy- and 3'-hydroxy-4'-methoxy-diclofenac), most of which are converted to glucuronide conjugates. Two of these phenolic metabolites are biologically active, but to a much smaller extent than diclofenac.

**Elimination**

Total systemic clearance of diclofenac from plasma is 263 ± 56 mL/min (mean value ±SD). The terminal half-life in plasma is 1 to 2 hours. Four of the metabolites, including the two active ones, also have short plasma half-lives of 1 to 3 hours. One metabolite, 3'-hydroxy-4'-methoxy-diclofenac has a much longer plasma half-life. However, this metabolite is virtually inactive.

About 60% of the administered dose is excreted in the urine as the glucuronide conjugate of the intact molecule and as metabolites, most of which are also converted to glucuronide conjugates. Less than 1% is excreted as unchanged substance. The rest of the dose is eliminated as metabolites through the bile in the faeces.

**Linearity/non-linearity**

The amount absorbed is in linear proportion to the size of the dose.

**Pharmacokinetics in special patient groups**

No relevant age-dependent differences in the drug’s absorption, metabolism, or excretion have been observed. However, in a few elderly patients a 15-minute intravenous infusion resulted in 50% higher plasma concentrations than expected from the data on young healthy subjects.

In patients suffering from renal impairment, no accumulation of the unchanged active substance can be inferred from the single-dose kinetics when applying the usual dosage schedule. At a creatinine clearance of <10 mL/min, the calculated steady-state plasma levels of the hydroxy metabolites are about 4 times higher than in normal subjects. However, the metabolites are ultimately cleared through the bile.

In patients with chronic hepatitis or non-decompensated cirrhosis, the kinetics and metabolism of diclofenac are the same as in patients without liver disease.

5.3 **Preclinical safety data**

Preclinical data from acute and repeated dose toxicity studies, as well as from genotoxicity, mutagenicity, and carcinogenicity studies with diclofenac revealed no specific hazard for humans at the intended therapeutic doses. In standard preclinical animal studies, there was no evidence that diclofenac had a teratogenic potential in mice, rats or rabbits.

Diclofenac had no influence on the fertility of parent animals in rats. Except for minimal fetal effects at maternally toxic doses, the prenatal, perinatal and postnatal development of the offspring was not affected.

Administration of NSAIDs (including diclofenac) inhibited ovulation in the rabbit and implantation and placentation in the rat, and led to premature closure of the ductus arteriosus in the pregnant rat. Maternally toxic doses of diclofenac were associated with dystocia, prolonged gestation, decreased fetal survival, and intrauterine growth retardation in rats. The slight effects of diclofenac on reproduction parameters and delivery as well as constriction of the ductus arteriosus in utero are
pharmacologic consequences of this class of prostaglandin synthesis inhibitors (see section 4.3 and 4.6).

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Mannitol; sodium metabisulphite (E223); benzyl alcohol; propylene glycol; water for injection; sodium hydroxide; nitrogen, pure.
Information might differ in some countries.

6.2 Incompatibilities
As a rule, Voltaren solution for injection should not be mixed with other injection solutions. Infusion solutions of sodium chloride 0.9 % or glucose 5 % without sodium bicarbonate as an additive present a risk of supersaturation, possibly leading to formation of crystals or precipitates. Infusion solutions other than those recommended should not be used.

6.3 Shelf life
2 years.

6.4 Special precautions for storage
Store below 30°C.
Store in the original package in order to protect from light.

6.5 Nature and contents of container
Colourless glass ampoules of 3 mL in packs of 5.

6.6 Special precautions for disposal and handling
The following directions for intramuscular injection must be followed in order to avoid damage to a nerve or other tissue at the injection site.

To be injected either intramuscularly by deep intragluteal injection into the upper outer quadrant using aseptic technique, or intravenously by slow infusion after dilution in accordance with the following instructions. Each ampoule is for single use only. The solution should be used immediately after opening. Any unused contents should be discarded.

Depending on the intended duration of infusion (see Dosage of administration), mix 100 to 500 mL of isotonic saline (sodium chloride 0.9 % solution) or glucose 5 % solution buffered with sodium bicarbonate injectable solution (0.5 mL of 8.4 % or 1 mL of 4.2 % or a corresponding volume of a different concentration) taken from a freshly opened container; add the contents of one Voltaren ampoule to this solution. Only clear solutions should be used. If crystals or precipitates are observed, the infusion solution should not be used.

7 MEDICINE SCHEDULE
Prescription medicine
8 SPONSOR

Novartis New Zealand Limited
109 Carlton Gore Road
Newmarket
AUCKLAND 1023

PO Box 99102
Newmarket
Auckland 1149
Telephone: 0800 354 335

* = Registered Trademark

9 DATE OF FIRST APPROVAL

21 May 1980

10 DATE OF REVISION OF THE TEXT

07 September 2017

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Adoption of SPC format</td>
</tr>
<tr>
<td>4.6</td>
<td>Update of Medsafe NSAIDs class effect wording on the potential risk of spontaneous abortion.</td>
</tr>
</tbody>
</table>

Internal document code: vli190917INZ based on CDS dated 14-Jan-2016